The initial generation of COMT inhibitors was excessively toxic to be approved for use, but second-generation COMT inhibitors, including tolcapone (TOL), have been found to be effective in providing symptomatic relief for certain Parkinson’s patients with an acceptable toxicity profile. This evidence concerns the gene COMT and Parkinson disease.